ALK and non-small cell lung carcinoma: Moreover, the simultaneous inhibition of CTLA-4 and PD-L1, as exemplified by the combination of nivolumab and ipilimumab, has been investigated as a first-line therapy for patients with advanced NSCLC lacking EGFR/ALK alterations.